Aspirin in primary prevention: sex and baseline risk matter.
Algra
Ale
A
Department of Neurology, Rudolf Magnus Institute of Neuroscience, University Medical Centre Utrecht, Utrecht, Netherlands. a.algra@umcutrecht.nl
Greving
Jacoba P
JP
D000328:Adult; D000368:Aged; D001241:Aspirin / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D015201:Meta-Analysis as Topic; D008875:Middle Aged; D018579:Patient Selection; D011322:Primary Prevention / Q000191:economics / Q000379:methods*; D019057:Quality-Adjusted Life Years; D012107:Research Design; D012307:Risk Factors; D017678:Sex Distribution; D013927:Thrombosis / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*
D005343:Fibrinolytic Agents; D001241:Aspirin